| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
Liu Q, Zhang Y, Zhang J, et al. Efficacy and safety of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk[J]. Front Oncol, 2024, 14: 1374149. DOI: 10.3389/fonc.2024.1374149.
|
| [9] |
Lyu N, Wang X, Li JB, et al. Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase Ⅲ trial (FOHAIC-1)[J]. J Clin Oncol, 2022, 40(5): 468-480. DOI: 10.1200/JCO.21.01963.
|
| [10] |
唐英, 闫雪琴, 张志刚, 等. 肝癌介入术后早期下床活动时间的Meta分析[J]. 中国实用护理杂志, 2017, 33(10): 791-796.
|
| [11] |
|
| [12] |
李含英, 尤国美, 潘琴, 等. 经桡动脉置管行持续灌注化疗治疗肝癌的安全性和舒适性研究[J]. 浙江医学, 2020, 42(21): 2366-2367, 2373.
|
| [13] |
|
| [14] |
|
| [15] |
An C, Wei R, Yao W, et al. Association of serum AFP trajectories and hepatocellular carcinoma outcomes after hepatic arterial infusion chemotherapy: a longitudinal, multicenter study[J]. Cancer Med, 2024, 13(11): e7319. DOI: 10.1002/cam4.7319.
|
| [16] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
|
| [17] |
Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1): 6. DOI: 10.1038/s41572-020-00240-3.
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
王志强, 彭俏菁, 黎源, 等. 经股动脉DSA术后下肢不同制动时间对并发症发生率的影响[J]. 哈尔滨医药, 2021, 41(3): 65-66.
|
| [23] |
|
| [24] |
卢利云. 6例肝动脉灌注化疗治疗晚期原发性肝癌的护理体会[J]. 加速康复外科杂志, 2020, 3(3): 123-126.
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|